Amgen To Acquire Privately Held Teneobio For $900 Million In Cash With Future Contingent Milestone Payments
The Pharma Data
JULY 27, 2021
This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. About Teneobio Teneobio, Inc.
Let's personalize your content